Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00177138

Enrollment

Registered

2005-09-15

Start date

2004-07-31

Completion date

2006-11-30

Last updated

2013-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Campath Study, Pancreas After Kidney Transplantation, Alemtuzumab

Brief summary

This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1) immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin, tacrolimus, and MMF (Group 2). This study will investigate the first protocol that is both steroid-free and calcineurin inhibitor-free in pancreas after kidney transplant recipients.

Detailed description

Secondary objectives of the study are: 1. Compare the side effects of the immunosuppressive medications between both groups. This will include anaphylactic reactions, GI side-effects, bone marrow suppression, renal dysfunction, hypertension, hyperglycemic effects, and effects on lipid profile. 2. Compare the incidence of infections between both groups. Comparison parameters are: 1. Pancreas and kidney graft failure 2. Patient death 3. Clinical and biopsy documented rejection episodes 4. Patient dropout (non-compliance with the study protocol) 5. Kidney function as assessed by creatinine clearance or biopsy 6. Need to change immunosuppression regimen 7. Quality-adjusted Life Years

Interventions

DRUGTacrolimus

Starting POD #1 0.06 mg/kg/day in 2 divided doses;

DRUGAlemtuzumab

30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Previous kidney transplant from a living or deceased donor and a deceased- donor pancreas transplant. 2. Recipient age 18-60 years 3. Donor age 10-59 years 4. Females of childbearing potential should have a negative pregnancy test, and agree to practice birth control for the duration of the study. 5. Enteric or bladder drained pancreas transplant. \-

Exclusion criteria

1. Use of an investigational drug in the last 1-year. 2. Positive T or B cell crossmatch. 3. WBC\<3000 at enrollment 4. Platelet count \<50,000 at enrollment 5. History of malignancy (exclusive of minor skin cancers) 6. Inability to give informed consent 7. Systemic infections 8. Major active or chronic infections, including documented HIV infection (by any licensed ELISA and confirmation by Western Blot). 9. Serology negative for EBV pre-transplant. 10. No other previous organ transplants other than pancreas and/or kidney. -

Design outcomes

Primary

Measure	Time frame
Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.	2 years

Secondary

Measure	Time frame
The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026